CG Oncology (CGON) EBITDA (2023 - 2026)
CG Oncology (CGON) reported EBITDA of -$66.4 million for Q1 2026, down 57.3% on a YoY basis from -$155.5 million in Q1 2025, and down 36.32% quarter-over-quarter from -$48.7 million in Q4 2025.
CG Oncology (CGON) EBITDA (2023 - 2026) Analysis & Trends
CG Oncology has reported EBITDA for 4 years, with the latest figure at -$66.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 57.3% year-over-year to -$66.4 million; the trailing twelve-month figure through Mar 2026 stood at -$215.0 million (down 59.94% YoY), and the FY2025 full-year result was -$190.8 million, down 66.37% from the prior year.
- EBITDA for Q1 2026 stood at -$66.4 million, down from -$48.7 million in the prior quarter.
- The five-year high for EBITDA was -$9.7 million in Q1 2023, with the low at -$66.4 million in Q1 2026.
- Historically, EBITDA has averaged -$32.9 million across 4 years, with a median of -$28.3 million in 2024.
- Annual changes were most pronounced in 2024 — EBITDA tumbled 131.14% — and 2025, when it dropped 27.99%.
- CG Oncology's EBITDA stood at -$19.4 million in 2023, then plunged by 96.58% to -$38.0 million in 2024, then dropped by 27.99% to -$48.7 million in 2025, then tumbled by 36.32% to -$66.4 million in 2026.
- The last three EBITDA figures came in at -$66.4 million (Q1 2026), -$48.7 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | -66.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.39 Mn |
| Dec 31, 2025 | -48.70 Mn |
| Sep 30, 2025 | -51.13 Mn |
| Jun 30, 2025 | -48.74 Mn |
| Mar 31, 2025 | -42.20 Mn |
| Dec 31, 2024 | -38.05 Mn |
| Sep 30, 2024 | -28.30 Mn |
| Jun 30, 2024 | -25.85 Mn |
| Mar 31, 2024 | -22.47 Mn |
| Dec 31, 2023 | -19.36 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -12.33 Mn |
| Mar 31, 2023 | -9.72 Mn |